ISSN:
1619-0904
Keywords:
In vivo tissue engineering
;
Bone marrow transplantation
;
bFGF
;
Release system of angiogenic growth factors
;
Revascularization
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
,
Technology
Notes:
Abstract For successful in vivo tissue engineering, a growth factor release system will be useful. We adopted autologous bone marrow transplantation as an angiogenic growth factor release system. Bone marrow transplanted into a synthetic vascular prosthesis produced continuous synthesis of angiogenic growth factors, resulting in rapid neointima formation on the prosthesis after implantation. We expected a similar angiogenic phenomenon to occur if bone marrow was transplanted into ischemic myocardium. Bone marrow was transplanted into ischemic myocardium created in dogs. Marrow cells continued synthesis of angiogenic growth factors, which were effective in protecting the capillary network from ischemia, but not myocytes. Autologous bone marrow was injected intramuscularly into ischemic myocardium created in the left ventricular wall of dogs. Control operations were performed without bone marrow. On days 3 and 7, marrow cells survived, and their adjacent cells and the surrounding extracellular matrix were immunohistochemically bFGF reactive. At 3 weeks, no marrow cells were identified. Myocytes disappeared, but the capillary blood vessel networks remained. With some exceptions, these capillaries did not contain blood cell components. In the controls, scar tissue with a very small number of capillaries was formed. In conclusion, marrow cells survived for a short period of time after transplantation, and continued synthesis of angiogenic growth factors, which were effective in protecting endothelial cells from ischemia, but not myocytes. Therefore, the results also suggest that there are limitations in the treatment of ischemic myocardium using angiogenic growth factors alone.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01235530
Permalink
